ImmunityBio (NASDAQ:IBRX) Research Coverage Started at BTIG Research

BTIG Research assumed coverage on shares of ImmunityBio (NASDAQ:IBRX) in a research note issued to investors on Friday morning, Marketbeat Ratings reports. The brokerage issued a buy rating and a $6.00 target price on the stock.

A number of other equities research analysts have also recently issued reports on IBRX. EF Hutton Acquisition Co. I upgraded shares of ImmunityBio to a “strong-buy” rating in a report on Wednesday, October 23rd. D. Boral Capital reaffirmed a “buy” rating and issued a $30.00 target price on shares of ImmunityBio in a report on Monday, January 6th.

ImmunityBio Trading Down 5.5 %

NASDAQ IBRX opened at $2.42 on Friday. ImmunityBio has a 1 year low of $2.38 and a 1 year high of $10.53. The company has a fifty day simple moving average of $3.96 and a 200 day simple moving average of $4.33. The company has a market cap of $1.69 billion, a P/E ratio of -2.63 and a beta of 0.86.

Institutional Investors Weigh In On ImmunityBio

Several hedge funds have recently made changes to their positions in the stock. Captrust Financial Advisors acquired a new position in ImmunityBio in the 3rd quarter valued at approximately $41,000. Algert Global LLC acquired a new position in shares of ImmunityBio in the second quarter valued at $86,000. Virtu Financial LLC bought a new position in ImmunityBio in the third quarter worth $51,000. Dimensional Fund Advisors LP acquired a new stake in ImmunityBio during the second quarter worth $105,000. Finally, Mercer Global Advisors Inc. ADV bought a new stake in ImmunityBio in the 2nd quarter valued at $126,000. Institutional investors own 8.58% of the company’s stock.

About ImmunityBio

ImmunityBio, Inc, a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies.